- Regeneron's Phase 3 skin cancer miss adds to mounting failures in LAG-3Regeneron Pharmaceuticals’ LAG-3 inhibitor called fianlimab has flunked a late-stage skin cancer trial, marking yet another blow for the drug class. The announcement follows a spate of recent cli…Endpoints · 2mo ago↗ source
- FDA approves AstraZeneca’s baxdrostat for certain patients with hypertensionOne of the key products underpinning AstraZeneca’s goal of hitting $80 billion in revenue by 2030 has been approved by the FDA, the drugmaker said Monday. The blood ...Endpoints · 2mo ago↗ source
- Makary resigns; Biogen reports Alzheimer’s data; and moreWelcome back to Endpoints Weekly. The biggest news this week was Marty Makary’s resignation from his role as FDA Commissioner. The announcement came days after reports emerged that President Donald…